A5078122039- Lung Cancer Treatments and Mutations
- Gastric Cancer Management and Outcomes
- Hepatocellular Carcinoma Treatment and Prognosis
- Lung Cancer Diagnosis and Treatment
- PI3K/AKT/mTOR signaling in cancer
- Synthesis and biological activity
- Colorectal Cancer Treatments and Studies
- Liver physiology and pathology
- Lung Cancer Research Studies
- Quinazolinone synthesis and applications
- Receptor Mechanisms and Signaling
- Pesticide Exposure and Toxicity
- Neuropeptides and Animal Physiology
- Scientific Measurement and Uncertainty Evaluation
- Monoclonal and Polyclonal Antibodies Research
- Schizophrenia research and treatment
- Neurotransmitter Receptor Influence on Behavior
- Retinoids in leukemia and cellular processes
- Statistical Methods and Bayesian Inference
- Enzyme function and inhibition
- Bipolar Disorder and Treatment
- Carcinogens and Genotoxicity Assessment
- Cholinesterase and Neurodegenerative Diseases
- Retinal Diseases and Treatments
- Chemotherapy-induced organ toxicity mitigation
Uppsala University
2009-2013
Abstract Osimertinib is a third-generation, irreversible, oral EGFR tyrosine kinase inhibitor (TKI) recommended as first-line treatment for patients with locally advanced/metastatic mutation–positive (EGFRm) non–small cell lung cancer (NSCLC). However, MET amplification/overexpression common acquired osimertinib resistance mechanism. Savolitinib an oral, potent, and highly selective MET-TKI; preliminary data suggest that combining savolitinib may overcome MET-driven resistance. A...
The port delivery system with ranibizumab (PDS) is designed to continuously deliver maintain therapeutic drug concentrations in the vitreous of eye for an extended duration. PDS has been evaluated treatment neovascular age-related macular degeneration Ladder (PDS 10, 40, and 100 mg/mL, refill exchanges as needed, versus monthly intravitreal 0.5 mg), Archway mg/mL 24-week exchanges, ongoing Portal exchanges) clinical trials. Data from Ladder, Archway, were used develop a population...
Savolitinib (AZD6094, HMPL-504, volitinib) is an oral, potent, and highly MET receptor TK inhibitor. This series of studies aimed to develop a pharmacokinetic-pharmacodynamic (PK/PD) model link inhibition phosphorylation (pMET) by savolitinib with anti-tumour activity.Cell line-derived xenograft (CDX) experiments using human lung cancer (EBC-1) gastric (MKN-45) cells were conducted in athymic nude mice variety doses schedules savolitinib. Tumour pMET changes growth calculated after 28 days....
<p>Supplementary Data text</p>
<p>Supplementary Figure S5</p>
<p>Supplementary Figure S2</p>
<p>Supplementary Figure S3</p>
<p>Supplementary Figure S4</p>
<p>Supplementary Figure S1</p>
<p>Supplementary Data text</p>
<p>Supplementary Figure S2</p>
<p>Supplementary Figure S5</p>
<p>Supplementary Figure S3</p>
<p>Supplementary Figure S4</p>
<div>Abstract<p>Osimertinib is a third-generation, irreversible, oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), recommended as first-line treatment for patients with locally advanced/metastatic EGFR-mutation positive (EGFRm) non-small cell lung cancer (NSCLC). However, MET-amplification/overexpression common acquired osimertinib resistance mechanism. Savolitinib an oral, potent, and highly selective MET-TKI; preliminary data suggest that combining...
<p>Supplementary Figure S1</p>
Abstract In oncology drug development, measuring concentrations at the tumor site and targeted receptor remains an ongoing challenge. Positron emission tomography (PET)‐imaging is a promising noninvasive method to quantify intratumor exposure of radiolabeled (biodistribution data) target saturation by treatment doses in vivo. Here, we present development application minimal physiologically‐based pharmacokinetic (mPBPK) modeling approach integrate biodistribution data quantitative platform...